NEW YORK, July 20 /PRNewswire/ -- Double Helix Consulting US, a division of London-based Double Helix Development group, today announced the appointment of Caryn Zieses to the position of Senior Consultant. Zieses joins a multidisciplinary team of highly experienced strategic pricing, reimbursement and market access consultants with extensive experience across the healthcare industry, which provides product commercialization services to firms in the pharmaceutical, biotechnology and medical device industries. DHC US provides services spanning the product lifecycle, including the following:
Drew Baker, President of Double Helix Consulting US, commented, "Caryn complements our international market access, pricing and reimbursement capabilities through her vast experience in planning and implementing product development and launch strategies for the US market. Her intimate knowledge of managed care market structure, formulary management, contracting strategies, and marketing communications strengthens Double Helix's ability to meet our clients' commercial objectives in the increasingly cost-conscious and value-driven US market."
Chief Executive Officer of Double Helix Development Group, Dr. Wayne Phillips, added, "Double Helix Consulting offers a premier set of services to assist our clients in optimizing product commercialization by enhancing market access through a truly global team of professionals with deep experience from both the client and consulting sides. As an example, our growing emerging markets practice provides clients with the intelligence to implement successful strategies in the world's largest and most rapidly developing economies. Caryn's experience in product planning and launch strategy bolsters our expanding capabilities."
Zieses joins the Double Helix Consulting US team from the Pricing & Reimbursement consulting practice of IMS Health. She has worked closely with both large and small pharmaceutical and biotech clients to deliver global strategic recommendations that would inform decisions related to drug pricing, market access, clinical trial design, value messaging, payer attitudes, forecasting, and commercial assessments. Her expertise in US payer trends spans both public and private organizations and the policy changes they continually face. She has extensive experience in a diverse set of therapy areas, in particular those related to neurosciences, pulmonology, immunology and ophthalmology. She also has four years of previous client services experience in the Equity Research division of Lehman Brothers. Caryn holds an MBA from the Kellogg School of Management, an MEM from Northwestern University, and a BSE in Chemical Engineering from the University of Pennsylvania.
|SOURCE Double Helix Consulting US|
Copyright©2009 PR Newswire.
All rights reserved